U.S., Feb. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07398222) titled 'Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study' on Jan. 28.
Brief Summary: Introduction
Obesity and type 2 diabetes mellitus constitute a global public health problem. Medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity are a modern therapeutic option for both diseases. Liraglutide, semaglutide, dulaglutide and tirzepatide are representatives of this drug class, whose mechanism of action results in delayed gastric emptying, reduced gastric motility and increased gastric volume.
Tirzepatide, however, presents a dual agonist action, combining GLP-1 ag...